COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04535700

Not reported

Not reported

2020-09-02

Completed

RCT

Randomized

Parallel

Open label

single-center

Treatment

inclusion criteria: adult patients > 18 years confirmed diagnosis of covid-19 or high clinical suspicion according to current criteria. diagnosis prior to admission of dm2. patients who provide their informed consent to participate in the study

under 18 years known hypersensitivity to the active ingredient or any of the drug's excipients. known history of heart failure or situation at the time of initiation of the heart failure study. hepatic failure. dialysis situation of diabetic ketoacidosis at the start of the study. diabetes mellitus different from type 2. active bladder cancer or a history of bladder cancer hematuria patients included in another experimental study with another drug. admission to the intensive care unit. patients requiring mechanical ventilation at the time of inclusion pregnancy lactation

2

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

18

100

Spain

Moderate/severe disease at enrollment

4: Moderate/severe disease at enrollment

8

Patients treated with pioglitazone, together with conventional treatment for COVID-19 infection, who during their admission evolve towards the need to receive support with mechanical ventilation, enter the ICU and / or die.

None

Phase 4

[{"arm_notes": "", "treatment_id": 993, "treatment_name": "Pioglitazone", "treatment_type": "Metabolic agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]